|
|
作者：CardiothoracicSurgery
*仅供医学专业人士参考
伴有残余结节放射学进展的多灶磨玻璃/贴壁样肺腺癌的异质性
AATS 2023
原文标题
Heterogeneity In the Population of Multifocal Ground-Glass/Lepidic Lung Adenocarcinoma with Radiographic Progression of Residual Nodules
作者及单位
Joseph Shrager , Invited Discussant , Stanford Health Care
Zhao Li , Abstract Presenter , Shanghai Pulmonary Hospital
背景
肺残余结节(RN)伴多灶磨玻璃/贴壁样(GG/L)肺腺癌的影像学进展，可能表现为非贴壁样为主型腺癌(非lppa)。本研究旨在分析这些患者的临床特征，探讨RNs组织病理学亚型(LPPA或非LPPA)的术前危险因素。
方法
本文回顾性研究了365例接受两次肺切除术的多灶性GG/L腺癌患者。切除的显性肿瘤(DT)是放射学上最具侵入性的肺部病变，其次显性肿瘤（DT）是肺残余结节（RN）表现出的放射学进展。比较LPPA组和非LPPA组在第二次DT组织病理学上的生存分析。采用单因素和多因素分析探讨与第二次DT非lppa相关的危险因素。
结果
伴有影像学进展的多灶性GG/L腺癌患者的5年总生存率和无复发生存率(RFS)分别为100.0%和98.5%，中位随访时间为55.4个月。14.8%的患者第二次DT表现为非lppa。第二次DT为非LPPA患者的5年RFS率明显低于LPPA患者(90.4% vs 100.0%， p<0.001)。多因素分析提示，BMI (OR=1.158, p=0.007)和二次DT的∆CT密度(OR=1.006, p<0.001)分别是二次DT非lppa组织病理学的独立危险因素。
结论
多灶性GG/L肺腺癌患者接受第二次放射学进展的RN手术后，预后仍然良好。第二组患者的组织病理学为非lppa, RFS较差。BMI和∆CT密度是预测第二次DT非lppa的危险因素。
作者简介
Joseph Shrager
Invited Discussant
Dr. Shrager is Professor of Cardiothoracic Surgery; Chief of the Division of Thoracic Surgery at Stanford University School of Medicine; and co-Director of the Thoracic Oncology Clinical Care Program within Stanford Cancer Institute. He also runs the Stanford Respiratory Muscle Research Laboratory.
Zhao Li
Abstract Presenter
Li Zhao, male, Ph.D., attending physician of thoracic surgery department of Shanghai Pulmonary Hospital; postdoctoral fellow of Tongji University (mentor: Professor Jiang Gening); graduated from Shanghai Jiaotong University School of Medicine with an eight-year clinical medicine degree in 2018 and obtained a doctorate in clinical medicine. Member of Shanghai Anti-Cancer Association.
He is mainly engaged in clinical comprehensive diagnosis and treatment of thoracic surgery, and has rich experience in clinical management of thoracic surgery.
The main research directions are:
Clinical translational study of hollow multi-shelled nanoparticle drug delivery system for repairing tracheobronchial defects and bronchopleural fistulas,
Prediction and prognosis of high-risk patients with multiple primary lung adenocarcinoma,
Predictive analysis of circulating tumor cells in the diagnosis, metastasis and recurrence of lung adenocarcinoma.
So far, 7 SCI papers have been published as the first author and co-first author, with a total impact factor (IF) of 72.26 and a total of 133 citations.
点赞或分享 让我们共同成长
翻译及审校：刘浩
点击“阅读原文”看摘要原文
原文地址：http://mp.weixin.qq.com/s?src=11×tamp=1683915174&ver=4524&signature=cd9ByPuPo9lbRAtoNxk-V2XBLO2t64uCxhpeaxlPNPd5uPKVkxMnl371ts-Cq2S6goWi-Du07xZ468c1sl4Uz84D5Lr4yW9Nfr5u1Lg8g96fGwDdYJhQimXG5dCD1LRl&new=1 |
|
